SiteOne Therapeutics

Executive Summary

SiteOne Therapeutics is a biopharmaceutical company developing novel, non-opioid small molecule therapeutics targeting specific sodium ion channels for severe neurological and psychiatric disorders, including chronic pain and CNS conditions. Founded in 2015 and based in South San Francisco, the company has raised $100 million to advance its pipeline. Its lead program focuses on Nav1.7 and Nav1.8 voltage-gated sodium channels, which are genetically validated pain targets. By selectively inhibiting these channels, SiteOne aims to deliver potent analgesia without the addictive liability of opioids or the side effects of non-selective sodium channel blockers. The company's approach addresses a significant unmet need in pain management, where safer, more effective non-opioid options are urgently required. SiteOne has advanced its lead candidate, ST-2427, into Phase 1 clinical trials for acute pain and potentially for chronic pain indications. Early preclinical data demonstrate favorable selectivity, pharmacokinetics, and a wide therapeutic window. In parallel, the company is exploring applications in other CNS disorders, such as epilepsy and migraine, where sodium channel dysfunction plays a key role. With a strong intellectual property estate and a seasoned management team, SiteOne is positioned to become a leader in non-opioid pain therapeutics. The next 12–18 months are critical as Phase 1 data readouts and potential partnership discussions could validate the platform and drive significant value inflection.

Upcoming Catalysts (preview)

• H2 2026Phase 1 data readout for lead candidate ST-2427 in acute pain65% success
• H1 2027IND filing for second-generation Nav1.8-selective inhibitor50% success
• 2026Potential partnership or licensing deal for pain or CNS programs40% success